We think intelligent long term investing is the way to go. But along the way some stocks are going to perform badly. Zooming in on an example, the 4SC AG (ETR:VSC) share price dropped 55% in the last ...

The considerable ownership by private companies in 4SC indicates that they collectively have a greater say in management and business strategy The top 2 shareholders own 70% of the company 22% of 4SC ...

We think intelligent long term investing is the way to go. But that doesn't mean long term investors can avoid big losses. Zooming in on an example, the 4SC AG (ETR:VSC) share price dropped 60% in the ...

4SC AG has announced that it has further continued its successful development in the 2012 financial year. The consolidated financial results according to IFRS published by the Company for both the ...

Planegg-Martinsried, Germany (pta007/11.09.2020/07:30 UTC+2) Maruho and 4SC agree to terminate their development agreement related to 4SC's Kv1.3 inhibitors. 4SC to reacquire all rights to the ...

PLANEGG-MARTINSRIED, Germany & TOKYO--(BUSINESS WIRE)--4SC AG (Frankfurt, Prime Standard: VSC) and Yakult Honsha Co.; Ltd. (Tokyo: 2267) today announced the grant of an exclusive license by 4SC to ...

4SC AG has announced clinical data of the Phase I 'AEGIS' trial with the anti-cancer compound 4SC-205 in tumour patients. All primary study objectives were achieved. A comprehensive safety and ...

Planegg-Martinsried, Germany, 22 March 2024 – 4SC AG (4SC, FSE Prime Standard: VSC) today published its financial results for the financial year ended 31 December 2023, presenting all material ...

4SC (FRA:VSC) has reported lackluster data from a Phase II trial of its liver cancer asset resminostat. The trial, which was run by 4SC’s Japanese partner Yakult Honsha, failed to detect an ...

Planegg-Martinsried, Germany, 18 October 2022 – 4SC AG (4SC, FSE Prime Standard: VSC) today provided a business update for the three months ended 30 September 2022, as well as its current outlook. The ...

- Resminostat/sorafenib combination therapy halts further disease progression in two thirds of patients (PFSR 66.6%) and achieves median progression-free survival (PFS) of 4.6 months - First ...

German biotech 4SC has filed its oral HDAC inhibitor Kinselby with the EMA, hoping to provide a much-needed new therapy for patients with the rare cancer cutaneous T-Cell lymphoma (CTCL). CTCL is a ...